Pharma news
Pharma
Representatives from the pharmaceutical and engineering industries have said that the decision to opt existing patents into the Unified Patent Court will be a strategic decision done on a case-by-case basis. 2 October 2015
Pharma
The Court of Justice of the European Union has clarified when pharmaceutical patent owners may rely on the Specific Mechanism to prevent parallel imports of their products. 2 October 2015
Pharma
An Advocate General in the Court of Justice of the European Union, Niilo Jääskinen, has clarified how the regulation for supplementary protection certificates should be interpreted concerning medicinal products made with a combination of active ingredients. 2 October 2015
Pharma
The CJEU’s decision in Forsgren has brought greater clarity to the scope of the SPC regulation, including whether a substance is an active ingredient, as Avi Toltzis and Penny Gilbert of Powell Gilbert explain. 1 October 2015
Pharma
The tussle between Teva and Amgen over the latter’s SPC for lipegfilgrastim is still playing out in Denmark’s IP court and may yet be referred to the CJEU. Michael Pitzner-Bruun of law firm Kromann Reumert reports. 1 October 2015
Pharma
The UK health secretary has been urged by a health campaigning group to issue a compulsory licence for a breast cancer patent owned by Swiss pharmaceutical company Roche. 1 October 2015
Pharma
The Warner-Lambert v Actavis case concerning second medical use patents has resulted in a carefully considered judgment and there are some clear lessons to be learnt, says Arty Rajendra of Rouse Legal. 1 October 2015
Africa
The international police organisation Interpol plays a vital role in connecting law enforcement and health authorities around the world in the fight against pharmaceutical crime. Aline Plançon reports. 1 October 2015
Americas
Pharmaceutical company Allergan has survived an attempt by hedge fund Ferrum Ferro Capital to invalidate a patent covering its Combigan drug after the Patent Trial and Appeal Board opted not to institute an inter partes review. 29 September 2015
Asia-Pacific
A Japanese lawyer has described a ruling by the Supreme Court of Japan as a “death sentence” for product-by-process patents and said it is a good time for drugs companies to challenge rivals’ patents. 29 September 2015